(NYSE: ADCT) Adc Therapeutics Sa's forecast annual revenue growth rate of 20.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Adc Therapeutics Sa's revenue in 2025 is $77,246,000.On average, 2 Wall Street analysts forecast ADCT's revenue for 2025 to be $8,767,077,852, with the lowest ADCT revenue forecast at $8,556,703,984, and the highest ADCT revenue forecast at $8,977,451,721. On average, 1 Wall Street analysts forecast ADCT's revenue for 2026 to be $13,117,429,457, with the lowest ADCT revenue forecast at $13,117,429,457, and the highest ADCT revenue forecast at $13,117,429,457.
In 2027, ADCT is forecast to generate $14,647,421,229 in revenue, with the lowest revenue forecast at $14,647,421,229 and the highest revenue forecast at $14,647,421,229.